Literature DB >> 18040054

Cancer risk management practices of noncarriers within BRCA1/2 mutation positive families in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer.

Sarah-Jane Dawson1, Melanie A Price, Mark A Jenkins, Joanne M McKinley, Phyllis N Butow, Sue-Anne McLachlan, Geoffrey J Lindeman, Prue Weideman, Michael L Friedlander, John L Hopper, Kelly-Anne Phillips.   

Abstract

PURPOSE: Women from BRCA mutation-positive families who do not carry the family-specific mutation are generally at average cancer risk and therefore do not require intensive risk management.
METHODS: Participants were female noncarriers from BRCA mutation-positive families who had responded to 3 yearly follow-up questionnaires and had chosen to either receive or not receive their genetic test result. In the former group, undertaking mammography younger than age 40 years or more than once every 2 years, clinical breast examination (CBE) more than yearly, breast self-examination (BSE) more than monthly, or any transvaginal ultrasound (TVU) or CA-125 was considered overscreening. Screening behaviors of women who did and did not know their genetic test result were compared. Logistic regression and nonparametric analyses were performed to identify demographic and psychosocial factors (respectively) associated with overscreening.
RESULTS: Of 325 eligible women, 116 knew their mutation status and 209 did not. For the first group, proportions overscreening were mammography, 53%; CBE, 10%; BSE, 11%; TVU, 7%; and CA-125, 10%. There were no significant differences in screening behaviors between the groups. In those aware of their mutation status, parous women were more likely to overuse mammography (odds ratio [OR] = 4.4; 95% CI, 1.1 to 17; P = .03) and women with one or more first-degree relative with ovarian cancer (OC) were more likely to overuse OC screening (TVU: OR = 6.00; 95% CI, 1.0 to 35.1; P = .047, and CA-125: OR = 6.50; 95% CI, 1.49 to 28.4; P = .013).
CONCLUSION: The reasons for overuse of screening (particularly mammography) by mutation noncarriers require additional elucidation given the potential for harm.

Entities:  

Mesh:

Year:  2007        PMID: 18040054     DOI: 10.1200/JCO.2007.11.0262

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  8 in total

1.  Intuition versus cognition: a qualitative exploration of how women understand and manage their increased breast cancer risk.

Authors:  Louise Heiniger; Phyllis N Butow; Margaret Charles; Melanie A Price
Journal:  J Behav Med       Date:  2015-03-28

2.  Breast and ovarian cancer screening of non-carriers from BRCA1/2 mutation-positive families: 2-year follow-up of cohorts from France and Quebec.

Authors:  Michel Dorval; Catherine Noguès; Pascaline Berthet; Jocelyne Chiquette; Marion Gauthier-Villars; Christine Lasset; Claude Picard; Marie Plante; Jacques Simard; Claire Julian-Reynier
Journal:  Eur J Hum Genet       Date:  2011-01-19       Impact factor: 4.246

3.  Comparison of the screening practices of unaffected noncarriers under 40 and between 40 and 49 in BRCA1/2 families.

Authors:  Christelle Duprez; Véronique Christophe; Isabelle Milhabet; Aurélie Krzeminski; Claude Adenis; Pascaline Berthet; Jean-Philippe Peyrat; Philippe Vennin
Journal:  J Genet Couns       Date:  2013-01-25       Impact factor: 2.537

4.  The effectiveness of a graphical presentation in addition to a frequency format in the context of familial breast cancer risk communication: a multicenter controlled trial.

Authors:  Lidewij Henneman; Jan C Oosterwijk; Christi J van Asperen; Fred H Menko; Caroline F Ockhuysen-Vermey; Piet J Kostense; Liesbeth Claassen; Daniëlle Rm Timmermans
Journal:  BMC Med Inform Decis Mak       Date:  2013-04-29       Impact factor: 2.796

5.  Cancer risk management strategies and perceptions of unaffected women 5 years after predictive genetic testing for BRCA1/2 mutations.

Authors:  Claire Julian-Reynier; Julien Mancini; Emmanuelle Mouret-Fourme; Marion Gauthier-Villars; Valérie Bonadona; Pascaline Berthet; Jean-Pierre Fricker; Olivier Caron; Elisabeth Luporsi; Catherine Noguès
Journal:  Eur J Hum Genet       Date:  2011-01-26       Impact factor: 4.246

6.  No evidence of excessive cancer screening in female noncarriers from BRCA1/2 mutation-positive families.

Authors:  S Guedaoura; S Pelletier; W D Foulkes; P Hamet; J Simard; N Wong; Z El Haffaf; J Chiquette; M Dorval
Journal:  Curr Oncol       Date:  2017-12-20       Impact factor: 3.677

7.  Clinical follow-up and breast and ovarian cancer screening of true BRCA1/2 noncarriers: a qualitative investigation.

Authors:  Sylvie Pelletier; Nora Wong; Zaki El Haffaf; William D Foulkes; Jocelyne Chiquette; Pavel Hamet; Jacques Simard; Michel Dorval
Journal:  Genet Med       Date:  2015-11-05       Impact factor: 8.822

8.  Design of the BRISC study: a multicentre controlled clinical trial to optimize the communication of breast cancer risks in genetic counselling.

Authors:  Caroline F Ockhuysen-Vermey; Lidewij Henneman; Christi J van Asperen; Jan C Oosterwijk; Fred H Menko; Daniëlle R M Timmermans
Journal:  BMC Cancer       Date:  2008-10-03       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.